TRANSFUSION-REALITY

Anemia in patients with myocardial infarction (MI) is a relatively frequent issue, resulting in poorer outcome. There is equipoise regarding which transfusion strategy is best, and there is an international consensus on the urgent need for a randomized trial. The REALITY study hypothesize that a "restrictive" transfusion strategy (triggered by Hb <= 8 g/ dL) will be clinically non-inferior to a "liberal" transfusion strategy (triggered by Hb <= 10g/ dL) but will be less costly.
TRANSFUSION-REALITY is a biological ancillary substudy of the REALITY study evaluating impact of RBC transfusion on platelet activation, aggregation and systemic biomarkers of thrombosis and inflammation in a series of biological measurements (baseline at randomization (before the first RBC transfusion (T0)), after RBC transfusion (on the next day after randomization and/or transfusion according to the group (T1)) and at discharge (T2) from the cardiology service.